Sun Pharmaceutical Industries Limited said on Thursday it will acquire U.S.-based Concert Pharmaceuticals for $576 million in cash to gain access to an experimental drug for treating patchy baldness.
https://www.pharmalive.com/wp-content/uploads/2022/12/ReutersSunPharma12-8-2022.jpg7531200Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2023-01-19 08:27:052023-01-19 09:03:37India’s Sun Pharma to acquire U.S.-based Concert for $576 mln
